Swiss stocks were in positive territory on Tuesday's close, with the Swiss Market Index up 0.32%, amid a quiet day of local economic news.
In the eurozone, the ZEW Indicator of Economic Sentiment improved to 9.5 points in June from -9.1 points in May, fueled by hopes that the Middle East conflict is nearing an end. The economic sentiment indicator for Germany, the eurozone's largest economy, also turned positive, rising by 20.7 points to 10.5 points in June.
On the geopolitical front, European Commission President Ursula von der Leyen met with UK Prime Minister Keir Starmer at the G7 Summit in Evian, France, discussing the situation in Ukraine and the Middle East. Swiss President Guy Parmelin is also set to meet Starmer this evening to discuss negotiations on a bilateral free trade deal.
Back home and in corporate news, Siegfried Holding (SFZN.SW) further expanded its large-scale drug substances offering with the launch of its new drug substances manufacturing facility in Minden, Germany. The Swiss contract development and manufacturing organization's stock shed 7.60% at closing.
Berenberg raised its price target for PolyPeptide Group (PPGN.SW) to 38 francs from 35 francs, with an unchanged buy recommendation on the stock, expressing optimism over the group's ability to achieve its revenue growth guidance for 2026. PolyPeptide's shares closed the session 5.65% higher.
"In the absence of any material newsflow, we take increasing confidence that operations at the newly expanded Braine-l'Alleud facility in Belgium are running as planned. The revenue contribution from this asset should provide sufficient support for the company to achieve the upper end of its 2026 revenue guidance, in our view," the research firm said. "In addition, PolyPeptide is expanding its site in Strasbourg, France, to support a large non-GLP-1 contract. We expect the ramp-up to begin in the second half of 2026, subject to approval from the regulatory authorities, with this reaching target utilisation as of 2027. We forecast this asset to contribute EUR50m of revenue from 2027E onwards."